Hans Schikan, CEO of Prosensa, on Rare Disease Drug Development

At the BIO CEO & Investor Conference in New York, BIO had the opportunity to speak with Hans Schikan, CEO of Prosensa, a company that targets rare diseases -- in particular Duchenne Muscular Dystrophy. He highlighted the important role patient advocacy organizations play in his company's drug development process and the industry's goal to help save lives and improve quality of life.